Your browser doesn't support javascript.
loading
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib.
Ellingson, Benjamin M; Kim, Grace Hyun J; Brown, Matt; Lee, Jihey; Salamon, Noriko; Steelman, Lori; Hassan, Islam; Pandya, Shuchi S; Chun, Saewon; Linetsky, Michael; Yoo, Bryan; Wen, Patrick Y; Mellinghoff, Ingo K; Goldin, Jonathan; Cloughesy, Timothy F.
Afiliação
  • Ellingson BM; UCLA Brain Tumor Imaging Laboratory, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Kim GHJ; UCLA Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Brown M; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Lee J; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Salamon N; UCLA Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Steelman L; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Hassan I; UCLA Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Pandya SS; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Chun S; UCLA Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Linetsky M; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Yoo B; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Wen PY; Servier Pharmaceuticals, LLC, Boston, Massachusetts, USA.
  • Mellinghoff IK; Servier Pharmaceuticals, LLC, Boston, Massachusetts, USA.
  • Goldin J; Servier Pharmaceuticals, LLC, Boston, Massachusetts, USA.
  • Cloughesy TF; UCLA Brain Tumor Imaging Laboratory, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Neuro Oncol ; 24(5): 770-778, 2022 05 04.
Article em En | MEDLINE | ID: mdl-34751786
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioma Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioma Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article